基質(zhì)金屬蛋白酶7(MMP7)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Matrix Metalloproteinase 7 (MMP7)
MPSL1; MAT; PUMP-1; Matrilysin Uterine; Matrilysin; Matrin; Pump-1 Protease; Uterine Metalloproteinase
- 編號(hào)SEA102Bo
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍15.6-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于6.2pg/mL.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3175 ¥ 4536 ¥ 20412 ¥ 38556 ¥ 317520
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)基質(zhì)金屬蛋白酶7(MMP7)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的基質(zhì)金屬蛋白酶7(MMP7)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 85-104 | 91 |
| heparin plasma(n=5) | 88-97 | 94 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的基質(zhì)金屬蛋白酶7(MMP7)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中基質(zhì)金屬蛋白酶7(MMP7)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-105% | 85-104% | 85-92% | 83-93% |
| heparin plasma(n=5) | 92-101% | 79-95% | 86-96% | 80-89% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將基質(zhì)金屬蛋白酶7(MMP7)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的基質(zhì)金屬蛋白酶7(MMP7)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的基質(zhì)金屬蛋白酶7(MMP7)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的基質(zhì)金屬蛋白酶7(MMP7)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA102Bo01 | 基質(zhì)金屬蛋白酶7(MMP7)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA102Bo01 | 基質(zhì)金屬蛋白酶7(MMP7)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA102Bo21 | 基質(zhì)金屬蛋白酶7(MMP7)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA102Bo | 基質(zhì)金屬蛋白酶7(MMP7)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA102Bo | 基質(zhì)金屬蛋白酶7(MMP7)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA102Bo | 基質(zhì)金屬蛋白酶7(MMP7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| British Journal of Pharmacology | A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model [PubMed: 20649573] |
| Neuroimmunomodulation | Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis Virus [Pubmed: source] |
| PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches [Plosone: Source] |
| Thromb Haemost. | Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke [Pubmed:24671655] |
| Histol Histopathol | Estrogen-deficient osteoporosis enhances the recruitment and activity of osteoclasts by breast cancer cells [PubMed: 26254457] |
| VirusDisease | Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection [Pubmed:26925446] |
| Am J Physiol Lung Cell Mol Physiol | Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosis [Pubmed:26993522] |
| Cellular Physiology and Biochemistry | The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells [pubmed:29224019] |
| s-space | Thyroid disrupting effects and associated mechanisms of TCPP in GH3 cell line and zebrafish (Danio rerio) larva and adult [10371/137708] |
| Science Translational Medicine | Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia. [pubmed:29167395] |
| Hepatology | Diagnostic Accuracy of Serum Matrix Metalloproteinase‐7 for Biliary Atresia [Pubmed: 30153340] |
| Journal of Pediatrics | Quantification of Serum Matrix Metallopeptide 7 Levels May Assist in the Diagnosis and Predict the Outcome for Patients with Biliary Atresia [Pubmed: 30853207] |
| Pediatrics | Serum MMP-7 in the Diagnosis of Biliary Atresia [Pubmed: 31604829] |
| Biomed Pharmacother | Human umbilical cord blood mononuclear cells protect against renal tubulointerstitial fibrosis in cisplatin-treated rats [Pubmed: 31710895] |
| LABORATORY INVESTIGATION | The synthetic toxin biliatresone causes biliary atresia in mice [Pubmed: 32681026] |
| diagnostics | Interstitial Score and Concentrations of IL-4R|á, PAR-2, and MMP-7 in Bronchoalveolar Lavage Fluid Could Be Useful Markers for Distinguishing Idiopathic Interstitial??- [33924683] |
| Cancer Cell Int | A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer [34215253] |
